{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T04:02:12Z","timestamp":1792814532574,"version":"4.5.0"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2020,10,6]],"date-time":"2020-10-06T00:00:00Z","timestamp":1601942400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2020,10,6]],"date-time":"2020-10-06T00:00:00Z","timestamp":1601942400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100002738","name":"Assistance Publique - H\u00f4pitaux de Paris","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002738","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs R D"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1007\/s40268-020-00319-y","type":"journal-article","created":{"date-parts":[[2020,10,6]],"date-time":"2020-10-06T23:04:29Z","timestamp":1602025469000},"page":"331-342","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Population Pharmacokinetic Model of Plasma and Cellular Mycophenolic Acid in Kidney Transplant Patients from the CIMTRE Study"],"prefix":"10.1007","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2696-8661","authenticated-orcid":false,"given":"Fran\u00e7ois","family":"Riglet","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Bertrand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aur\u00e9lie","family":"Barrail-Tran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9line","family":"Verstuyft","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hugues","family":"Michelon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henri","family":"Benech","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoine","family":"Durrbach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Val\u00e9rie","family":"Furlan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Barau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,10,6]]},"reference":[{"issue":"1","key":"319_CR1","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1097\/00007890-199701150-00008","volume":"63","author":"P Halloran","year":"1997","unstructured":"Halloran P, Mathew T, Tomlanovich S, Groth C, Hooftman L, Barker C. Mycophenolate mofetil in renal allograft recipients: a pooled efficacy analysis of three randomized, double-blind, clinical studies in prevention of rejection: the International Mycophenolate Mofetil Renal Transplant Study Groups. Transplantation. 1997;63(1):39\u201347.","journal-title":"Transplantation"},{"issue":"4","key":"319_CR2","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1097\/01.tp.0000200307.79962.48","volume":"81","author":"M Brunet","year":"2006","unstructured":"Brunet M, Cirera I, Martorell J, et al. Sequential determination of pharmacokinetics and pharmacodynamics of mycophenolic acid in liver transplant patients treated with mycophenolate mofetil. Transplantation. 2006;81(4):541\u20136. https:\/\/doi.org\/10.1097\/01.tp.0000200307.79962.48.","journal-title":"Transplantation"},{"issue":"3","key":"319_CR3","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1681\/ASN.2005101070","volume":"17","author":"RM van Hest","year":"2006","unstructured":"van Hest RM, Mathot RAA, Pescovitz MD, Gordon R, Mamelok RD, van Gelder T. Explaining variability in mycophenolic acid exposure to optimize mycophenolate mofetil dosing: a population pharmacokinetic meta-analysis of mycophenolic acid in renal transplant recipients. J Am Soc Nephrol. 2006;17(3):871\u201380. https:\/\/doi.org\/10.1681\/ASN.2005101070.","journal-title":"J Am Soc Nephrol"},{"issue":"5","key":"319_CR4","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1007\/s40262-017-0593-6","volume":"57","author":"TKL Kiang","year":"2018","unstructured":"Kiang TKL, Ensom MHH. Population pharmacokinetics of mycophenolic acid: an update. Clin Pharmacokinet. 2018;57(5):547\u201358. https:\/\/doi.org\/10.1007\/s40262-017-0593-6.","journal-title":"Clin Pharmacokinet"},{"issue":"8","key":"319_CR5","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1124\/dmd.32.8.775","volume":"32","author":"O Bernard","year":"2004","unstructured":"Bernard O, Guillemette C. The main role of UGT1A9 in the hepatic metabolism of mycophenolic acid and the effects of naturally occurring variants. Drug Metab Dispos Biol Fate Chem. 2004;32(8):775\u20138.","journal-title":"Drug Metab Dispos Biol Fate Chem."},{"issue":"1","key":"319_CR6","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1124\/dmd.104.001651","volume":"33","author":"N Picard","year":"2005","unstructured":"Picard N, Ratanasavanh D, Pr\u00e9maud A, Le Meur Y, Marquet P. Identification of the UDP-glucuronosyltransferase isoforms involved in mycophenolic acid phase II metabolism. Drug Metab Dispos Biol Fate Chem. 2005;33(1):139\u201346. https:\/\/doi.org\/10.1124\/dmd.104.001651.","journal-title":"Drug Metab Dispos Biol Fate Chem."},{"issue":"1","key":"319_CR7","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1038\/clpt.2009.205","volume":"87","author":"N Picard","year":"2010","unstructured":"Picard N, Yee SW, Woillard JB, et al. The role of organic anion-transporting polypeptides and their common genetic variants in mycophenolic acid pharmacokinetics. Clin Pharmacol Ther. 2010;87(1):100\u20138. https:\/\/doi.org\/10.1038\/clpt.2009.205.","journal-title":"Clin Pharmacol Ther"},{"issue":"10","key":"319_CR8","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1080\/00498254.2016.1235742","volume":"47","author":"H Kagaya","year":"2017","unstructured":"Kagaya H, Niioka T, Saito M, et al. Effect of hepatic drug transporter polymorphisms on the pharmacokinetics of mycophenolic acid in patients with severe renal dysfunction before renal transplantation. Xenobiotica Fate Foreign Compd Biol Syst. 2017;47(10):916\u201322. https:\/\/doi.org\/10.1080\/00498254.2016.1235742.","journal-title":"Xenobiotica Fate Foreign Compd Biol Syst."},{"issue":"12","key":"319_CR9","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.2217\/pgs.10.132","volume":"11","author":"H Michelon","year":"2010","unstructured":"Michelon H, K\u00f6nig J, Durrbach A, et al. SLCO1B1 genetic polymorphism influences mycophenolic acid tolerance in renal transplant recipients. Pharmacogenomics. 2010;11(12):1703\u201313. https:\/\/doi.org\/10.2217\/pgs.10.132.","journal-title":"Pharmacogenomics."},{"issue":"3","key":"319_CR10","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1111\/ajt.15214","volume":"19","author":"MD Stegall","year":"2019","unstructured":"Stegall MD, Somerville KT, Everly MJ, et al. The importance of drug safety and tolerability in the development of new immunosuppressive therapy for transplant recipients: the Transplant Therapeutics Consortium\u2019s position statement. Am J Transplant. 2019;19(3):625\u201332. https:\/\/doi.org\/10.1111\/ajt.15214.","journal-title":"Am J Transplant"},{"key":"319_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.12659\/aot.895664","volume":"21","author":"KM Gardiner","year":"2016","unstructured":"Gardiner KM, Tett SE, Staatz CE. Multinational evaluation of mycophenolic acid, tacrolimus, cyclosporin, sirolimus, and everolimus utilization. Ann Transplant. 2016;21:1\u201311. https:\/\/doi.org\/10.12659\/aot.895664.","journal-title":"Ann Transplant."},{"issue":"2 Suppl.","key":"319_CR12","doi-asserted-by":"publisher","first-page":"S244","DOI":"10.1097\/01.tp.0000186380.61251.fc","volume":"80","author":"T van Gelder","year":"2005","unstructured":"van Gelder T, Shaw LM. The rationale for and limitations of therapeutic drug monitoring for mycophenolate mofetil in transplantation. Transplantation. 2005;80(2 Suppl.):S244\u201353. https:\/\/doi.org\/10.1097\/01.tp.0000186380.61251.fc.","journal-title":"Transplantation"},{"issue":"2","key":"319_CR13","doi-asserted-by":"publisher","first-page":"341","DOI":"10.2215\/CJN.07111009","volume":"5","author":"DRJ Kuypers","year":"2010","unstructured":"Kuypers DRJ, Meur YL, Cantarovich M, et al. Consensus report on therapeutic drug monitoring of mycophenolic acid in solid organ transplantation. Clin J Am Soc Nephrol. 2010;5(2):341\u201358. https:\/\/doi.org\/10.2215\/CJN.07111009.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"2","key":"319_CR14","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.trre.2010.06.001","volume":"25","author":"SE Tett","year":"2011","unstructured":"Tett SE, Saint-Marcoux F, Staatz CE, et al. Mycophenolate, clinical pharmacokinetics, formulations, and methods for assessing drug exposure. Transplant Rev. 2011;25(2):47\u201357. https:\/\/doi.org\/10.1016\/j.trre.2010.06.001.","journal-title":"Transplant Rev."},{"issue":"10","key":"319_CR15","doi-asserted-by":"publisher","first-page":"2012","DOI":"10.1097\/TP.0000000000002762","volume":"103","author":"DK Metz","year":"2019","unstructured":"Metz DK, Holford N, Kausman JY, et al. Optimizing mycophenolic acid exposure in kidney transplant recipients: time for target concentration intervention. Transplantation. 2019;103(10):2012\u201330. https:\/\/doi.org\/10.1097\/TP.0000000000002762.","journal-title":"Transplantation"},{"issue":"2","key":"319_CR16","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.trre.2011.01.002","volume":"25","author":"Y Le Meur","year":"2011","unstructured":"Le Meur Y, Borrows R, Pescovitz MD, et al. Therapeutic drug monitoring of mycophenolates in kidney transplantation: report of The Transplantation Society consensus meeting. Transplant Rev (Orlando). 2011;25(2):58\u201364. https:\/\/doi.org\/10.1016\/j.trre.2011.01.002.","journal-title":"Transplant Rev (Orlando)."},{"issue":"6","key":"319_CR17","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1016\/S0009-9236(98)90058-3","volume":"64","author":"MD Hale","year":"1998","unstructured":"Hale MD, Nicholls AJ, Bullingham RES, et al. The pharmacokinetic-pharmacodynamic relationship for mycophenolate mofetil in renal transplantation. Clin Pharmacol Ther. 1998;64(6):672\u201383. https:\/\/doi.org\/10.1016\/S0009-9236(98)90058-3.","journal-title":"Clin Pharmacol Ther"},{"issue":"2","key":"319_CR18","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1097\/TP.0b013e31815feede","volume":"85","author":"P Falck","year":"2008","unstructured":"Falck P, \u00c5sberg A, Guldseth H, et al. Declining intracellular T-lymphocyte concentration of cyclosporine A precedes acute rejection in kidney transplant recipients. Transplantation. 2008;85(2):179\u201384. https:\/\/doi.org\/10.1097\/TP.0b013e31815feede.","journal-title":"Transplantation"},{"issue":"1","key":"319_CR19","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1111\/j.1432-2277.2011.01365.x","volume":"25","author":"A Capron","year":"2012","unstructured":"Capron A, Lerut J, Latinne D, Rahier J, Haufroid V, Wallemacq P. Correlation of tacrolimus levels in peripheral blood mononuclear cells with histological staging of rejection after liver transplantation: preliminary results of a prospective study. Transpl Int. 2012;25(1):41\u20137. https:\/\/doi.org\/10.1111\/j.1432-2277.2011.01365.x.","journal-title":"Transpl Int"},{"issue":"6","key":"319_CR20","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/j.clinbiochem.2014.12.005","volume":"48","author":"MT Thi","year":"2015","unstructured":"Thi MT, Mourad M, Capron A, Musuamba Tshinanu F, Vincent M-F, Wallemacq P. Plasma and intracellular pharmacokinetic\u2013pharmacodynamic analysis of mycophenolic acid in de novo kidney transplant patients. Clin Biochem. 2015;48(6):401\u20135. https:\/\/doi.org\/10.1016\/j.clinbiochem.2014.12.005.","journal-title":"Clin Biochem"},{"issue":"6","key":"319_CR21","doi-asserted-by":"publisher","first-page":"429","DOI":"10.2165\/00003088-199834060-00002","volume":"34","author":"RES Bullingham","year":"1998","unstructured":"Bullingham RES, Nicholls AJ, Kamm BR. Clinical pharmacokinetics of mycophenolate mofetil. Clin Pharmacokinet. 1998;34(6):429\u201355. https:\/\/doi.org\/10.2165\/00003088-199834060-00002.","journal-title":"Clin Pharmacokinet"},{"issue":"7","key":"319_CR22","doi-asserted-by":"publisher","first-page":"463","DOI":"10.2165\/11312600-000000000-00000","volume":"48","author":"RM van Hest","year":"2009","unstructured":"van Hest RM, van Gelder T, Vulto AG, Shaw LM, Mathot RAA. Pharmacokinetic modelling of the plasma protein binding of mycophenolic acid in renal transplant recipients. Clin Pharmacokinet. 2009;48(7):463\u201376. https:\/\/doi.org\/10.2165\/11312600-000000000-00000.","journal-title":"Clin Pharmacokinet"},{"issue":"3","key":"319_CR23","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1111\/j.1365-2125.2004.02235.x","volume":"59","author":"BA Atcheson","year":"2005","unstructured":"Atcheson BA, Taylor PJ, Mudge DW, et al. Mycophenolic acid pharmacokinetics and related outcomes early after renal transplant. Br J Clin Pharmacol. 2005;59(3):271\u201380. https:\/\/doi.org\/10.1111\/j.1365-2125.2004.02235.x.","journal-title":"Br J Clin Pharmacol"},{"issue":"2","key":"319_CR24","doi-asserted-by":"publisher","first-page":"76","DOI":"10.2174\/187231208784040951","volume":"2","author":"N Ansermot","year":"2008","unstructured":"Ansermot N, Rebsamen M, Chabert J, et al. Influence of ABCB1 gene polymorphisms and P-glycoprotein activity on cyclosporine pharmacokinetics in peripheral blood mononuclear cells in healthy volunteers. Drug Metab Lett. 2008;2(2):76\u201382.","journal-title":"Drug Metab Lett"},{"issue":"5","key":"319_CR25","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1517\/17425251003601953","volume":"6","author":"C Giraud","year":"2010","unstructured":"Giraud C, Manceau S, Treluyer J-M. ABC transporters in human lymphocytes: expression, activity and role, modulating factors and consequences for antiretroviral therapies. Expert Opin Drug Metab Toxicol. 2010;6(5):571\u201389. https:\/\/doi.org\/10.1517\/17425251003601953.","journal-title":"Expert Opin Drug Metab Toxicol."},{"issue":"5","key":"319_CR26","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1038\/clpt.2012.79","volume":"92","author":"K Kock","year":"2012","unstructured":"Kock K, Brouwer KL. A perspective on efflux transport proteins in the liver. Clin Pharmacol Ther. 2012;92(5):599\u2013612. https:\/\/doi.org\/10.1038\/clpt.2012.79.","journal-title":"Clin Pharmacol Ther"},{"issue":"17","key":"319_CR27","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.2217\/pgs-2018-0114","volume":"19","author":"L-Q Li","year":"2018","unstructured":"Li L-Q, Chen D-N, Li C-J, et al. Impact of\u00a0UGT2B7\u00a0and ABCC2\u00a0genetic polymorphisms on mycophenolic acid metabolism in Chinese renal transplant recipients. Pharmacogenomics. 2018;19(17):1323\u201334. https:\/\/doi.org\/10.2217\/pgs-2018-0114.","journal-title":"Pharmacogenomics."},{"issue":"1","key":"319_CR28","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1159\/000180580","volume":"16","author":"DW Cockcroft","year":"1976","unstructured":"Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16(1):31\u201341.","journal-title":"Nephron."},{"issue":"1\u20132","key":"319_CR29","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.jchromb.2007.03.008","volume":"853","author":"H B\u00e9nech","year":"2007","unstructured":"B\u00e9nech H, Hasco\u00ebt S, Furlan V, Pruvost A, Durrbach A. Development and validation of an LC\/MS\/MS assay for mycophenolic acid in human peripheral blood mononuclear cells. J Chromatogr B Analyt Technol Biomed Life Sci. 2007;853(1\u20132):168\u201374. https:\/\/doi.org\/10.1016\/j.jchromb.2007.03.008.","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci."},{"issue":"5","key":"319_CR30","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1182\/blood.V57.5.894.894","volume":"57","author":"GB Segel","year":"1981","unstructured":"Segel GB, Cokelet GR, Lichtman MA. The measurement of lymphocyte volume: importance of reference particle deformability and counting solution tonicity. Blood. 1981;57(5):894\u20139.","journal-title":"Blood"},{"issue":"7","key":"319_CR31","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1007\/s40262-017-0603-8","volume":"57","author":"H Colom","year":"2018","unstructured":"Colom H, Andreu F, van Gelder T, et al. Prediction of free from total mycophenolic acid concentrations in stable renal transplant patients: a population-based approach. Clin Pharmacokinet. 2018;57(7):877\u201393. https:\/\/doi.org\/10.1007\/s40262-017-0603-8.","journal-title":"Clin Pharmacokinet"},{"issue":"3","key":"319_CR32","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1177\/0049124199027003005","volume":"27","author":"AE Raftery","year":"1999","unstructured":"Raftery AE. Bayes factors and BIC: comment on \u201cA Critique of the Bayesian Information Criterion for Model Selection\u201d. Sociol Methods Res. 1999;27(3):411\u201327. https:\/\/doi.org\/10.1177\/0049124199027003005.","journal-title":"Sociol Methods Res."},{"issue":"2","key":"319_CR33","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1208\/s12248-011-9255-z","volume":"13","author":"M Bergstrand","year":"2011","unstructured":"Bergstrand M, Hooker AC, Wallin JE, Karlsson MO. Prediction-corrected visual predictive checks for diagnosing nonlinear mixed-effects models. AAPS J. 2011;13(2):143\u201351. https:\/\/doi.org\/10.1208\/s12248-011-9255-z.","journal-title":"AAPS J"},{"issue":"10","key":"319_CR34","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.2165\/00003088-200544100-00006","volume":"44","author":"RM van Hest","year":"2005","unstructured":"van Hest RM, van Gelder T, Vulto AG, Mathot RAA. Population pharmacokinetics of mycophenolic acid in renal transplant recipients. Clin Pharmacokinet. 2005;44(10):1083\u201396. https:\/\/doi.org\/10.2165\/00003088-200544100-00006.","journal-title":"Clin Pharmacokinet"},{"issue":"6","key":"319_CR35","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1007\/s10928-009-9136-6","volume":"36","author":"BCM de Winter","year":"2009","unstructured":"de Winter BCM, van Gelder T, Sombogaard F, Shaw LM, van Hest RM, Mathot RAA. Pharmacokinetic role of protein binding of mycophenolic acid and its glucuronide metabolite in renal transplant recipients. J Pharmacokinet Pharmacodyn. 2009;36(6):541\u201364. https:\/\/doi.org\/10.1007\/s10928-009-9136-6.","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"11","key":"319_CR36","doi-asserted-by":"publisher","first-page":"1654","DOI":"10.1177\/0091270011429567","volume":"52","author":"H Li","year":"2012","unstructured":"Li H, Mager DE, Bemer MJ, et al. A limited sampling schedule to estimate mycophenolic acid area under the concentration-time curve in hematopoietic cell transplantation recipients. J Clin Pharmacol. 2012;52(11):1654\u201364. https:\/\/doi.org\/10.1177\/0091270011429567.","journal-title":"J Clin Pharmacol"},{"issue":"7","key":"319_CR37","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1093\/clinchem\/41.7.1011","volume":"41","author":"I Nowak","year":"1995","unstructured":"Nowak I, Shaw LM. Mycophenolic acid binding to human serum albumin: characterization and relation to pharmacodynamics. Clin Chem. 1995;41(7):1011\u20137.","journal-title":"Clin Chem"},{"issue":"1","key":"319_CR38","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2165\/11536640-000000000-00000","volume":"50","author":"CMT Sherwin","year":"2011","unstructured":"Sherwin CMT, Fukuda T, Brunner HI, Goebel J, Vinks AA. The evolution of population pharmacokinetic models to describe the enterohepatic recycling of mycophenolic acid in solid organ transplantation and autoimmune disease. Clin Pharmacokinet. 2011;50(1):1\u201324. https:\/\/doi.org\/10.2165\/11536640-000000000-00000.","journal-title":"Clin Pharmacokinet"},{"issue":"6","key":"319_CR39","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1111\/j.1365-2125.2006.02841.x","volume":"63","author":"RM van Hest","year":"2007","unstructured":"van Hest RM, van Gelder T, Bouw R, et al. Time-dependent clearance of mycophenolic acid in renal transplant recipients. Br J Clin Pharmacol. 2007;63(6):741\u201352. https:\/\/doi.org\/10.1111\/j.1365-2125.2006.02841.x.","journal-title":"Br J Clin Pharmacol"},{"issue":"2","key":"319_CR40","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/S1053-2498(00)00525-8","volume":"20","author":"T Sawamoto","year":"2001","unstructured":"Sawamoto T, van Gelder T, Christians U, Okamura N, Jacobsen W, Benet L. Membrane transport of mycophenolate mofetil and its active metabolite, mycophenolic acid in MDCK and MDR1-MDCK cell monolayers. J Heart Lung Transplant. 2001;20(2):234\u20135.","journal-title":"J Heart Lung Transplant"},{"issue":"3\u20134","key":"319_CR41","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/j.trim.2008.05.009","volume":"19","author":"J Wang","year":"2008","unstructured":"Wang J, Figurski M, Shaw LM, Burckart GJ. The impact of P-glycoprotein and Mrp2 on mycophenolic acid levels in mice. Transpl Immunol. 2008;19(3\u20134):192\u20136. https:\/\/doi.org\/10.1016\/j.trim.2008.05.009.","journal-title":"Transpl Immunol"},{"issue":"4","key":"319_CR42","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1097\/FPC.0b013e3282f7046f","volume":"18","author":"S Crettol","year":"2008","unstructured":"Crettol S, Venetz J-P, Fontana M, et al. Influence of ABCB1 genetic polymorphisms on cyclosporine intracellular concentration in transplant recipients. Pharmacogenet Genom. 2008;18(4):307\u201315. https:\/\/doi.org\/10.1097\/FPC.0b013e3282f7046f.","journal-title":"Pharmacogenet Genom"},{"issue":"5","key":"319_CR43","doi-asserted-by":"publisher","first-page":"631","DOI":"10.2174\/138945011795378487","volume":"12","author":"V Haufroid","year":"2011","unstructured":"Haufroid V. Genetic polymorphisms of ATP-binding cassette transporters ABCB1 and ABCC2 and their impact on drug disposition. Curr Drug Targ. 2011;12(5):631\u201346. https:\/\/doi.org\/10.2174\/138945011795378487.","journal-title":"Curr Drug Targ"},{"issue":"5811","key":"319_CR44","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1126\/science.1135308","volume":"315","author":"C Kimchi-Sarfaty","year":"2007","unstructured":"Kimchi-Sarfaty C, Oh JM, Kim I-W, et al. A \u201csilent\u201d polymorphism in the MDR1 gene changes substrate specificity. Science. 2007;315(5811):525\u20138. https:\/\/doi.org\/10.1126\/science.1135308.","journal-title":"Science"},{"issue":"11","key":"319_CR45","doi-asserted-by":"publisher","first-page":"2146","DOI":"10.1248\/bpb.31.2146","volume":"31","author":"K Sugiyama","year":"2008","unstructured":"Sugiyama K, Isogai K, Toyama A, et al. Pharmacodynamic parameters of immunosuppressive drugs are not correlated with age, duration of dialysis, percentage of lymphocytes or lymphocyte stimulation index in renal transplant recipients. Biol Pharm Bull. 2008;31(11):2146\u20139. https:\/\/doi.org\/10.1248\/bpb.31.2146.","journal-title":"Biol Pharm Bull"},{"issue":"1","key":"319_CR46","doi-asserted-by":"publisher","first-page":"17","DOI":"10.2165\/11318110-000000000-00000","volume":"49","author":"C Bazzoli","year":"2010","unstructured":"Bazzoli C, Jullien V, Tiec CL, Rey E, Mentr\u00e9 F, Taburet A-M. Intracellular pharmacokinetics of antiretroviral drugs in HIV-infected patients, and their correlation with drug action. Clin Pharmacokinet. 2010;49(1):17\u201345. https:\/\/doi.org\/10.2165\/11318110-000000000-00000.","journal-title":"Clin Pharmacokinet"},{"issue":"5","key":"319_CR47","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1111\/j.1365-2125.2011.04140.x","volume":"73","author":"CMT Sherwin","year":"2012","unstructured":"Sherwin CMT, Sagcal-Gironella ACP, Fukuda T, Brunner HI, Vinks AA. Development of population PK model with enterohepatic circulation for mycophenolic acid in patients with childhood-onset systemic lupus erythematosus. Br J Clin Pharmacol. 2012;73(5):727\u201340. https:\/\/doi.org\/10.1111\/j.1365-2125.2011.04140.x.","journal-title":"Br J Clin Pharmacol"},{"issue":"2","key":"319_CR48","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.trre.2010.12.001","volume":"25","author":"M Cantarovich","year":"2011","unstructured":"Cantarovich M, Brown NW, Ensom MHH, et al. Mycophenolate monitoring in liver, thoracic, pancreas, and small bowel transplantation: a consensus report. Transpl Rev. 2011;25(2):65\u201377. https:\/\/doi.org\/10.1016\/j.trre.2010.12.001.","journal-title":"Transpl Rev."}],"container-title":["Drugs in R&D"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40268-020-00319-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40268-020-00319-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40268-020-00319-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,6]],"date-time":"2021-10-06T06:04:58Z","timestamp":1633500298000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40268-020-00319-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,6]]},"references-count":48,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["319"],"URL":"https:\/\/doi.org\/10.1007\/s40268-020-00319-y","relation":{},"ISSN":["1174-5886","1179-6901"],"issn-type":[{"value":"1174-5886","type":"print"},{"value":"1179-6901","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,6]]},"assertion":[{"value":"6 October 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This work was supported by a grant from the Hospital Clinical Research Program of the French Ministry of Health. The funders had no role in the study design, data collection and analysis, decision to publish or preparation of the manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Fran\u00e7ois Riglet, Julie Bertrand, Aur\u00e9lie Barrail-Tran, C\u00e9line Verstuyft, Hugues Michelon, Henri Benech, Antoine Durrbach, Val\u00e9rie Furlan and Caroline Barau have no conflicts of interest that are directly relevant to the content of this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest\/competing interests"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Patients signed informed consent regarding publishing their data.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The data supporting the findings of this study are available on request to the corresponding author. The data are not publicly available because of privacy or ethical restrictions.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Monolix codes are available upon request to the corresponding author.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"AD and VF designed the research. CB, ABT and VF performed the assays of plasma MPA concentrations and participated in the clinical and pharmacokinetic interpretation of the study. HB performed the assay of the cellular MPA concentrations. CV carried out the genotyping. FR analysed the data and performed the pharmacokinetic modelling under the supervision of JB. All authors participated in writing the manuscript.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 contributions"}}]}}